NanoViricides Inc Dossier
Qualitative Analysis
Business overview
NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage biopharmaceutical company pioneering the development of broad-spectrum antiviral therapies based on its proprietary host-mimetic nanomedicine platform. The company's unique technology designs "nanoviricides" that mimic host cell surface receptors, luring and trapping virus particles to neutralize them before they can infect healthy cells. This mechanism is designed to be highly resilient against viral mutations and variants. The company's lead drug candidate, NV-387, is a novel broad-spectrum antiviral that has successfully completed a Phase Ia/Ib human clinical safety and tolerability trial and is ready to enter Phase II clinical efficacy trials. NV-387 has demonstrated ultra-broad antiviral activity in preclinical models against multiple pathogens, including COVID-19, RSV, Influenza A, Mpox, Smallpox, and Ebola.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead drug candidate NV-387, a broad-spectrum host-mimetic antiviral, into an adaptive Phase II clinical trial in the DRC to treat Mpox Clade I and Clade II infections.
Expected impact: Establish human clinical efficacy and safety for NV-387, paving the way for potential FDA/EMA filings and stockpiling contracts under pandemic preparedness programs.
Proposing and preparing for a Phase II clinical trial of NV-387 Oral Gummies to treat the Bundibugyo Ebolavirus outbreak in the DRC and Uganda.
Expected impact: Provide an easily scalable, oral therapeutic option with escape-resistant features to combat lethal Ebola outbreaks where no approved treatments exist.
Securing external capital through registered direct offerings and shelf registrations to fund ongoing clinical programs and extend the operational runway.
Expected impact: Mitigate the risk of cash depletion and provide the financial flexibility required to sustain operations and support the broader NV-387 pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Om Sai Clinical Research serves as the primary CRO responsible for designing, preparing, and executing the Phase II clinical trials of NV-387 for both Mpox and Ebola in the Democratic Republic of Congo.
Terms: Financial terms of the CRO services agreement are not publicly disclosed.
NanoViricides holds a worldwide, exclusive, perpetual license to TheraCour's polymeric micelle nanomedicine technology for the treatment of specified human viral diseases.
Terms: Governed by a Memorandum of Understanding (MoU) for the development of drugs based on TheraCour's proprietary intellectual property and know-how.